Skip to main content
Top
Published in: Clinical Rheumatology 1/2012

Open Access 01-01-2012 | Review Article

An update on the pathology and clinical management of gouty arthritis

Author: Emilio B. Gonzalez

Published in: Clinical Rheumatology | Issue 1/2012

Login to get access

Abstract

Gouty arthritis is an inflammatory condition associated with debilitating clinical symptoms, functional impairments, and a substantial impact on quality of life. This condition is initially triggered by the deposition of monosodium urate crystals into the joint space. This causes an inflammatory cascade resulting in the secretion of several proinflammatory cytokines and neutrophil recruitment into the joint. While generally effective, currently available agents are associated with a number of adverse events and contraindications that complicate their use. Based on our increased understanding of the inflammatory pathogenesis of gouty arthritis, several new agents are under development that may provide increased efficacy and reduced toxicity.
Literature
1.
go back to reference Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40(1):37–42PubMedCrossRef Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40(1):37–42PubMedCrossRef
2.
go back to reference Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35PubMedCrossRef Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35PubMedCrossRef
3.
go back to reference Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31(8):1582–1587PubMed Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31(8):1582–1587PubMed
4.
go back to reference Riedel AA, Nelson M, Wallace K et al (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10(6):308–314PubMedCrossRef Riedel AA, Nelson M, Wallace K et al (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10(6):308–314PubMedCrossRef
5.
go back to reference Choi HK, Mount DB, Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143(7):499–516PubMed Choi HK, Mount DB, Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143(7):499–516PubMed
6.
go back to reference Becker MA, Ruoff GE (2010) What do I need to know about gout? J Fam Pract 59(6 Suppl):S1–S8PubMed Becker MA, Ruoff GE (2010) What do I need to know about gout? J Fam Pract 59(6 Suppl):S1–S8PubMed
7.
go back to reference Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516–521PubMedCrossRef Shi Y, Evans JE, Rock KL (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957):516–521PubMedCrossRef
8.
go back to reference Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241PubMedCrossRef Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241PubMedCrossRef
9.
go back to reference Joosten LA, Netea MG, Mylona E et al (2010) Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 62(11):3237–3248PubMedCrossRef Joosten LA, Netea MG, Mylona E et al (2010) Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 62(11):3237–3248PubMedCrossRef
10.
go back to reference Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56(10):3183–3188PubMedCrossRef Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56(10):3183–3188PubMedCrossRef
11.
go back to reference Torres R, Macdonald L, Croll SD et al (2009) Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68(10):1602–1608PubMedCrossRef Torres R, Macdonald L, Croll SD et al (2009) Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 68(10):1602–1608PubMedCrossRef
12.
go back to reference Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69(11):1907–1912PubMedCrossRef Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69(11):1907–1912PubMedCrossRef
13.
go back to reference Zwerina J, Redlich K, Polzer K et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104(28):11742–11747PubMedCrossRef Zwerina J, Redlich K, Polzer K et al (2007) TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104(28):11742–11747PubMedCrossRef
14.
go back to reference Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324PubMedCrossRef Zhang W, Doherty M, Bardin T et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324PubMedCrossRef
15.
go back to reference Terkeltaub RA, Furst DE, Bennett K et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068PubMedCrossRef Terkeltaub RA, Furst DE, Bennett K et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068PubMedCrossRef
16.
go back to reference Jordan KM, Cameron JS, Snaith M et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46(8):1372–1374CrossRef Jordan KM, Cameron JS, Snaith M et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46(8):1372–1374CrossRef
17.
go back to reference Keenan RT, O'Brien WR, Lee KH et al (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124(2):155–163PubMedCrossRef Keenan RT, O'Brien WR, Lee KH et al (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124(2):155–163PubMedCrossRef
18.
go back to reference Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L (2010) Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 40(3):210–214PubMedCrossRef Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L (2010) Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 40(3):210–214PubMedCrossRef
19.
go back to reference So A, De ST, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28PubMedCrossRef So A, De ST, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28PubMedCrossRef
20.
go back to reference Terkeltaub R, Sundy JS, Schumacher HR et al (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68(10):1613–1617PubMedCrossRef Terkeltaub R, Sundy JS, Schumacher HR et al (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68(10):1613–1617PubMedCrossRef
22.
go back to reference So A, De MM, Pikhlak A et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064–3076PubMedCrossRef So A, De MM, Pikhlak A et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064–3076PubMedCrossRef
23.
go back to reference Schlesinger N, De MM, Pikhlak A et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53PubMedCrossRef Schlesinger N, De MM, Pikhlak A et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53PubMedCrossRef
24.
go back to reference Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25–32PubMedCrossRef Salliot C, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68(1):25–32PubMedCrossRef
25.
go back to reference Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093–1103PubMedCrossRef Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093–1103PubMedCrossRef
26.
go back to reference Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363(9417):1277–1281PubMedCrossRef Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363(9417):1277–1281PubMedCrossRef
27.
go back to reference Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52(3):916–923PubMedCrossRef Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52(3):916–923PubMedCrossRef
28.
go back to reference Schumacher HR Jr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540–1548PubMedCrossRef Schumacher HR Jr, Becker MA, Wortmann RL et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540–1548PubMedCrossRef
29.
go back to reference Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461PubMedCrossRef Becker MA, Schumacher HR Jr, Wortmann RL et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461PubMedCrossRef
30.
go back to reference Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63PubMedCrossRef Becker MA, Schumacher HR, Espinoza LR et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12(2):R63PubMedCrossRef
31.
go back to reference Becker MA, Macdonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N (2008) Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27(6):585–591PubMedCrossRef Becker MA, Macdonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N (2008) Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 27(6):585–591PubMedCrossRef
32.
go back to reference Wortmann RL, Macdonald PA, Hunt B, Jackson RL (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397PubMedCrossRef Wortmann RL, Macdonald PA, Hunt B, Jackson RL (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397PubMedCrossRef
33.
go back to reference Hershfield MS, Roberts LJ, Ganson NJ et al (2010) Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107(32):14351–14356PubMedCrossRef Hershfield MS, Roberts LJ, Ganson NJ et al (2010) Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107(32):14351–14356PubMedCrossRef
34.
go back to reference Sundy JS, Becker MA, Baraf HSB et al (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 58(9):2882–2891PubMedCrossRef Sundy JS, Becker MA, Baraf HSB et al (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 58(9):2882–2891PubMedCrossRef
35.
go back to reference Baraf HBB, Matsumoto AK, Maroli AM, Waltrip RW (2008) Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 58(11):3632–3634PubMedCrossRef Baraf HBB, Matsumoto AK, Maroli AM, Waltrip RW (2008) Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 58(11):3632–3634PubMedCrossRef
36.
go back to reference Sundy JS, Baraf HS, Yood RA et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306(7):711–720PubMedCrossRef Sundy JS, Baraf HS, Yood RA et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306(7):711–720PubMedCrossRef
Metadata
Title
An update on the pathology and clinical management of gouty arthritis
Author
Emilio B. Gonzalez
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 1/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1877-0

Other articles of this Issue 1/2012

Clinical Rheumatology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.